NCT05853432View on ClinicalTrials.gov

A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy

CompletedOBSERVATIONAL
Enrollment

157

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

May 2, 2022

Study Completion Date

May 2, 2022

Conditions
HR+/HER2- Advanced or Metastatic Breast Cancer
Trial Locations (1)

Unknown

Novartis Pharmaceuticals, Dublin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT05853432 - A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy | Biotech Hunter | Biotech Hunter